Navigation Links
Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences
Date:4/7/2011

CHAPEL HILL, N.C., April 7, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at two upcoming CHI conferences.  Dr. Fernandes will present at the Second Annual Anti-Inflammatories: Small Molecule Approaches Conference at 5 p.m. PDT, April 12, at the Hilton San Diego Resort in San Diego.  Her presentation is entitled "Macrolides as a New Class of Orally Active Anti-Inflammatory Agents." Her presentation will include a discussion on the mechanism of macrolide action as anti-inflammatory agents and the use of macrolides in COPD patients. Data on the potent anti-inflammatory activities of solithromycin (CEM-101), Cempra's fluoroketolide candidate in Phase 2 clinical development for community-acquired bacterial pneumonia (CABP), as well as novel macrolides without antibacterial activity will be presented.

Dr. Fernandes will present at the Fifth Annual Resistance is Futile: The Challenge of Antibacterial Drug Development Conference at 10:45 a.m. PDT, April 13, at the Hilton San Diego Resort in San Diego.  Her presentation is entitled "Solithromycin: A Well-Tolerated Fluoroketolide with Broad Spectrum, Potent Activity" and will provide an overview of the potential clinical value of an oral and intravenous macrolide in treating drug-resistant pathogens.

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at www.cempra.com.

Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com

Tony Russo, Ph.D.
Russo Partners, LLC
(212) 845-4251
Tony.russo@russopartnersllc.com


'/>"/>
SOURCE Cempra Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™
3. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
4. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
5. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
6. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
7. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
8. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
9. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
10. Reportlinker Adds Global: Pharmaceuticals Industry Guide
11. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Research and Markets has announced the addition of the "Pharmaceutical Contract ... ... for the US, Canada , Japan ... Rest of World. Annual estimates and forecasts are provided for the period ... markets. Market data and analytics are derived from primary and secondary research. ...
(Date:2/17/2017)... LOUIS , Feb. 17, 2017   FormFast ... has announced a new partnership with Engage , ... the United States . FormFast will serve as ... of Engage,s implementations with MEDITECH .  ... provides essential functionality to complement and enhance the electronic ...
(Date:2/17/2017)... YORK , Feb. 17, 2017  Noble Capital ... on ESSA Pharma Inc. (Nasdaq: EPIX ). ... Research, Kumar Raja , PhD. ESSA ... for castration resistant prostate cancer (CRPC). Its lead compound ... blocks the amino-terminal domain of the androgen receptor, thereby ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... 2017 , ... Park Cities Pet Sitter President, Joette White, has been featured ... network. The episode, which was posted this week, features a 30-minute interview of ... Park Cities Pet Sitter’s being awarded the 2017 National Association of Professional Pet Sitter’s ...
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is a comprehensive ... NC. Dr. Brian Seese leads the practice as a skilled and highly credentialed dentist ... Smiles by Seese serves patients of all ages with excellence in general, restorative, and ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... tools that allow for the electronic prescribing of controlled and non-controlled substances plus ... Ninety percent of pharmacies in the United States now accept electronic prescriptions, according ...
(Date:2/17/2017)... Rancho Palos Verdes, CA (PRWEB) , ... February ... ... well-being, and emotional flow is Dr. Carol Francis' goals for each ... Federation Retreat Conference, Dr. Carol Francis will demonstrate five different brainwave tools which ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today announced that it ... Fla., February 19-23. Visitors to the company’s booth (#1778) will be the first ... signatures solution in healthcare . , Since it first introduced Electronic Signature ...
Breaking Medicine News(10 mins):